Illinois is currently home to 2681 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Post Mortem Tissue Donation of Pediatric Tumor Tissues and Cells
NCT05120518
Recruiting
The objective of this study is to utilize all donated pediatric tumor tissues and cells obtained from autopsy to prospectively develop novel patient derived orthotopic xenograft (PDOX) mouse models as well as in vitro cell culture model systems for pediatric cancers, and also provide tissue samples to other researchers and organizations (eg, CBTN, DIPG Registry, COG).
Gender:
All
Ages:
All
Trial Updated:
11/03/2021
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Pediatric Cancer
Register for Updates
Anesthesia Consent Process
NCT05102487
Recruiting
Currently at University of Chicago Medical Center (UCMC) consent for anesthesia is obtained verbally by qualified anesthesia providers. Later this year, we will be moving to a written informed consent form for anesthesia that must be signed by patients before proceeded with elective surgery. We aim to study patient satisfaction and retention of information presented before and after this change is made. After consent for anesthesia is obtained, study personnel will approach patients >= 18 years... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/19/2021
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Anesthesia Risks, Anesthesia Consent, Anesthesia, Consent Retention, Patient Satisfaction
Register for Updates
Soluble Corn Fiber for Promoting Executive Function Study
NCT05066425
Recruiting
The overarching aim of this study is to test the influence of daily consumption of a soluble corn fiber (SCF) known i.e., PROMITOR® Soluble Fibre™ for cognitive function among middle and older-aged adults.
Gender:
All
Ages:
Between 45 years and 75 years
Trial Updated:
10/01/2021
Locations: University of Illinois at Urbana-Champaign, Urbana, Illinois
Conditions: Health
Register for Updates
A Study to Evaluate the Safety and Efficacy of RQC for AMD
NCT05062486
Recruiting
To evaluate the safety and efficacy of resveratrol, quercetin, and curcumin in combination (RQC) over 2 years in patients with age-related macular degeneration (AMD).
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
09/20/2021
Locations: Zaparackas M.D. & Knepper M.D. Ph.D., Ltd, Chicago, Illinois
Conditions: Age-related Macular Degeneration
Register for Updates
Continuous Monitoring and Control of Hypoglycemia
NCT03340831
Recruiting
Evaluate safety of non-adjunctive CGM use in CGM naive participants.
Gender:
All
Ages:
2 years and above
Trial Updated:
09/17/2021
Locations: Northshore University Health System, Skokie, Illinois
Conditions: Diabetes
Register for Updates
Glanatec(R) for Descemet Stripping in Fuch's Endothelial Dystrophy
NCT03249337
Recruiting
In brief, the objective of this study is to investigate whether the drug Glanatec ® which is approved in Japan for glaucoma and ocular hypertension, can be used in patients with Fuchs endothelial dystrophy who have had a descemet stripping procedure without endothelial keratoplasty. While some limited data exists as a proof of concept in in vitro or animal studies, and Glanatec® has been successfully used in a recently published case series for this indication, there is insufficient data to show... Read More
Gender:
All
Ages:
Between 18 years and 91 years
Trial Updated:
08/09/2021
Locations: NorthShore University HealthSystem, Glenview, Illinois
Conditions: Fuchs' Endothelial Dystrophy
Register for Updates
Dietary Sodium-Restriction (DIS) and Renal Meals (RM) for Hemodialysis (HD)(DISaRM-HD)
NCT04991441
Recruiting
Chronic volume overload (VO) is a primary factor responsible for the excessive cardiovascular morbidity and mortality in hemodialysis (HD) patients. VO is caused in part by excessive fluid intake that is secondary to the consumption of a high salt diet. HD patients are often counselled to restrict their dietary sodium intake to help manage thirst and reduce their interdialytic weight gain (IDWG). However, data from recently published investigations demonstrate that dietary counseling alone may b... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/04/2021
Locations: University of Illinois at Urbana-Champaign, Urbana, Illinois
Conditions: Kidney Failure, Chronic, Dietary Modification
Register for Updates
CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer
NCT01985828
Recruiting
The primary objective of this study is to document the effectiveness of Cyberknife stereotactic body radiotherapy (SBRT) in the treatment of intermediate and high-risk localized prostate cancer defined by biochemical Disease-Free Survival (bDFS), using Phoenix and American Society of Therapeutic Radiation and Oncology (ASTRO) definitions, at 5 years. During the prostate-specific antigen era, an ever-increasing percentage of men with prostate cancer have presented with clinically localized, pote... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
07/19/2021
Locations: Advocate Lutheran General Hospital, Park Ridge, Illinois
Conditions: Prostate Adenocarcinoma
Register for Updates
Examining Health Literacy in Biorepository Consents
NCT04953169
Recruiting
Previous research has shown that most parents would allow their child's leftover blood to be included in a de-identified biorepository using opt-out consent in an outpatient setting. In a pilot study to evaluate Pediatric Intensive Care Unit (PICU) parents' preferences and comprehension of a written opt-in consent to include their child's sample in a biorepository, the investigators showed 19% of parents did not agree to participate in the Biobank, more than the 8.7% reported in other settings.... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/03/2021
Locations: Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Pediatric, Critical Illness, Consent
Register for Updates
Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation
NCT02981914
Recruiting
This pilot study has been designed to investigate the safety of pembrolizumab treatment for disease relapse following allogeneic stem cell transplant (alloSCT). Pembrolizumab will be administered at a fixed dose of 200 mg IV every 3 weeks. Approximately 12-26 patients with relapsed MDS, AML, or mature B cell (B-NHL, cHL) malignancies that have relapsed following alloSCT will be enrolled on this trial. Pembrolizumab treatment will be administered for up to 24 months, provided that neither disease... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/29/2021
Locations: University of Chicago, Chicago, Illinois
Conditions: Classical Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Register for Updates
Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder
NCT04948151
Recruiting
This study is looking to minimize side effects, while maintaining and potentially improving the therapeutic benefit to patients suffering from Female Sexual Arousal Disorder by providing a topical preparation of Sildenafil locally to the vulvar-vaginal tissue.
Gender:
Female
Ages:
21 years and above
Trial Updated:
06/24/2021
Locations: Great Lakes Clinical Trials, Chicago, Illinois
Conditions: Female Sexual Arousal Disorder
Register for Updates
JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation
NCT04429191
Recruiting
This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine, in subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) undergoing allogenic blood stem cell transplantation.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/08/2021
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: MYELODYSPLASTIC SYNDROME; MDS, ACUTE MYELOID LEUKEMIA; AML
Register for Updates